CPH •
Healthcare •
Biotechnology •
Quote as of 08/26/2026 16:59
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeCPH
Market Capitalization132,205 mln
Float58.96 mln
Earnings Date11/05/2026
EPS
80.93
Exceptional
P / E
26.73
Elevated
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-2.67
Likely reliable
1-Year Forecast
2,410
Modest upside
Relative Strength
93
/ 100
Top performer
Business Description
Founded in Copenhagen in 1998, Genmab is a Danish biotechnology company focused on developing antibody-based treatments for cancer and other serious diseases. Its commercial portfolio includes therapies for blood cancers such as large B-cell lymphoma, multiple myeloma, and cervical cancer, among others. The company has a broad pipeline of treatments in development targeting a range of solid tumors and blood disorders, and works alongside major pharmaceutical partners including Johnson & Johnson, Pfizer, AbbVie, and Bristol Myers Squibb.
